Expert Review of Anti-infective Therapy最新文献_第4页

Artificial intelligence and prescription of antibiotic therapy: present and future. 人工智能与抗生素治疗处方：现在与未来。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-18 DOI: 10.1080/14787210.2024.2386669

Daniele Roberto Giacobbe, Cristina Marelli, Sabrina Guastavino, Alessio Signori, Sara Mora, Nicola Rosso, Cristina Campi, Michele Piana, Ylenia Murgia, Mauro Giacomini, Matteo Bassetti

{"title":"Artificial intelligence and prescription of antibiotic therapy: present and future.","authors":"Daniele Roberto Giacobbe, Cristina Marelli, Sabrina Guastavino, Alessio Signori, Sara Mora, Nicola Rosso, Cristina Campi, Michele Piana, Ylenia Murgia, Mauro Giacomini, Matteo Bassetti","doi":"10.1080/14787210.2024.2386669","DOIUrl":"https://doi.org/10.1080/14787210.2024.2386669","url":null,"abstract":"Introduction: In the past few years, the use of artificial intelligence in healthcare has grown exponentially. Prescription of antibiotics is not exempt from its rapid diffusion, and various machine learning (ML) techniques, from logistic regression to deep neural networks and large language models, have been explored in the literature to support decisions regarding antibiotic prescription.Areas covered: In this narrative review, we discuss promises and challenges of the application of ML-based clinical decision support systems (ML-CDSSs) for antibiotic prescription. A search was conducted in PubMed up to April 2024.Expert opinion: Prescribing antibiotics is a complex process involving various dynamic phases. In each of these phases, the support of ML-CDSSs has shown the potential, and also the actual ability in some studies, to favorably impacting relevant clinical outcomes. Nonetheless, before widely exploiting this massive potential, there are still crucial challenges ahead that are being intensively investigated, pertaining to the transparency of training data, the definition of the sufficient degree of prediction explanations when predictions are obtained through black box models, and the legal and ethical framework for decision responsibility whenever an antibiotic prescription is supported by ML-CDSSs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections. 皮癣菌的抗真菌耐药性--回顾流行病学、诊断挑战和处理 indotineae 毛癣菌感染的治疗策略。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-18 DOI: 10.1080/14787210.2024.2390629

Aditya K Gupta, Tong Wang, Avantika Mann, Shruthi Polla Ravi, Mesbah Talukder, Sara A Lincoln, Hui-Chen Foreman, Baruch Kaplan, Eran Galili, Vincent Piguet, Avner Shemer, Wayne L Bakotic

{"title":"Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections.","authors":"Aditya K Gupta, Tong Wang, Avantika Mann, Shruthi Polla Ravi, Mesbah Talukder, Sara A Lincoln, Hui-Chen Foreman, Baruch Kaplan, Eran Galili, Vincent Piguet, Avner Shemer, Wayne L Bakotic","doi":"10.1080/14787210.2024.2390629","DOIUrl":"10.1080/14787210.2024.2390629","url":null,"abstract":"Introduction: There is an increasing number of reports of Trichophyton indotineae infections. This species is usually poorly responsive to terbinafine.Areas covered: A literature search was conducted in May 2024. T.indotineae infections detected outside the Indian subcontinent are generally associated with international travel. Reports of local spread are mounting.As a newly identified dermatophyte species closely related to the T. mentagrophytes complex with limited genetic and phenotypic differences, there is an unmet need to develop molecular diagnosis for T. indotineae. Terbinafine has become less effective as a first-line agent attributed to mutations in the squalene epoxidase gene (Leu393Phe, Phe397Leu). Alternative therapies include itraconazole for a longer time-period or a higher dose (200 mg/day or higher). Generally, fluconazole and griseofulvin are not effective. In some cases, especially when the area of involvement is relatively small, topical non-allylamine antifungals may be an option either as monotherapy or in combination with oral therapy. In instances when the patient relapses after apparent clinical cure then itraconazole may be considered. Good antifungal stewardship should be considered at all times.Expert opinion: When both terbinafine and itraconazole are ineffective, options include off-label triazoles (voriconazole and posaconazole). We present four patients responding to these newer triazoles.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of antibiotic resistance in clinical isolates of Mycobacterium kansasii: a systematic review and meta-analysis. 堪萨斯霉菌临床分离株的抗生素耐药性流行情况：系统回顾和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-02-06 DOI: 10.1080/14787210.2024.2313051

Negar Narimisa, Forough Goodarzi, Narjess Bostanghadiri, Faramarz Masjedian Jazi

{"title":"Prevalence of antibiotic resistance in clinical isolates of Mycobacterium kansasii: a systematic review and meta-analysis.","authors":"Negar Narimisa, Forough Goodarzi, Narjess Bostanghadiri, Faramarz Masjedian Jazi","doi":"10.1080/14787210.2024.2313051","DOIUrl":"10.1080/14787210.2024.2313051","url":null,"abstract":"Introduction: The prevalence of diseases caused by non-tuberculous mycobacteria (NTM), including M. kansasii, is increasing, necessitating further information to guide prevention, control, and treatment strategies.Areas covered: A comprehensive analysis of articles published until February 2023 was conducted on PubMed, Web of Science, and Scopus databases to investigate antibiotic resistance in M. kansasii species. Stata software version 17 was employed for all analyses.Expert opinion: A total of 1647 articles were obtained through database search. After removing duplicates and unrelated studies, 17 cross-sectional studies that examined the breakpoints proposed by CLSI were included. The rates of resistance of M. kansasii to various antibiotics were as follows: clarithromycin (0%), rifampin (1%), amikacin (0%), ciprofloxacin (14%), linezolid (0%), moxifloxacin (0%), rifabutin (1%), doxycycline (96%), and SXT (49%). Our findings underscore the importance of managing and monitoring the use of these antibiotics, as well as the need for further studies to elucidate the exact mechanism of M. kansasii resistance to these antibiotics.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape. 针对呼吸道合胞病毒的鼻内抗病毒药物：当前的治疗开发前景。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-09 DOI: 10.1080/14787210.2024.2378185

Victor Baba Oti, Adi Idris, Nigel A J McMillan

{"title":"Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape.","authors":"Victor Baba Oti, Adi Idris, Nigel A J McMillan","doi":"10.1080/14787210.2024.2378185","DOIUrl":"10.1080/14787210.2024.2378185","url":null,"abstract":"Introduction: Respiratory syncytial virus (RSV) causes bronchiolitis and other respiratory issues in immunocompromised individuals, the elderly, and children. After six decades of research, we have only recently seen the approval of two RSV vaccines, Arexvy and Abrysvo. Direct-acting antivirals against RSV have been more difficult to develop with ribavirin and palivizumab giving very modest reductions in hospitalizations and no differences in mortality. Recently, nirsevimab was licensed and has proven to be much more effective when given prophylactically. These are delivered intravenously (IV) and intramuscularly (IM), but an intranasal (IN) antiviral has several advantages in terms of ease of use, lower resource need, and acting at the site of infection.Areas covered: In this paper, we review the available literature on the current pre-clinical research landscape of anti-RSV therapeutics tested for IN delivery.Expert opinion: As RSV is a respiratory virus that infects both the upper and lower respiratory tracts, efforts are focused on developing a therapeutic that can be delivered via the nasal route. The rationale is to directly target the replicating virus with an obvious respiratory tract tropism. This approach will not only pave the way for a nasal delivery approach aimed at reducing respiratory viral illness but also controlling aerosol virus transmission.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use. COVID-19 大流行对初级保健中抗生素使用的长期影响：优化抗菌药物使用的经验教训。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-03-12 DOI: 10.1080/14787210.2024.2328333

Thais de Pando, Santiago Grau, Alexander Almendral, Daniel Echeverría-Esnal, Sergi Hernández, Enric Limon, Caridad Pontes

{"title":"Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use.","authors":"Thais de Pando, Santiago Grau, Alexander Almendral, Daniel Echeverría-Esnal, Sergi Hernández, Enric Limon, Caridad Pontes","doi":"10.1080/14787210.2024.2328333","DOIUrl":"10.1080/14787210.2024.2328333","url":null,"abstract":"Background: Lockdowns due to the COVID-19 pandemic was associated with changes in the pattern of use of antimicrobials, but persistence of changes after lockdowns has not been described. The objective was to describe the number of patients with dispensed antibiotic treatment and consumption of antibiotics in outpatients from primary care in Catalonia 18 months after the end of the emergency period.Research design and methods: Data for the COVID-19 pandemic period was obtained from March 2020 to December 2021. Four high transmission rate (Rt > 100) periods were established. To compare data, a simple Bayesian structural time series model was used.Results: The observed number of patients with dispensed antibiotics decreased respect to the estimated, especially during the four high transmission rate periods: April-May 2020 (lockdown period) (-42.57% and -42.68%); December 2020-February 2021 (-41.65%, -49.97% and -43.64%); October 2021 (-16.23%), and December 2021 (-20.16%). Overall antibiotic consumption was reduced by 23.37% (p = 0.002). These differences were mainly observed in those ≤ 15 years.Conclusions: We describe the reduction in the number of patients with dispensed antibiotics and antibiotic consumption after the COVID-19 lockdown persisted in a period of recovery of healthcare accessibility. This information may help to improve antimicrobial use at the primary care level.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain. 在西班牙，用异唑康唑与先用两性霉素 B 脂质体再用泊沙康唑治疗侵袭性霉菌病的经济影响比较。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-03-18 DOI: 10.1080/14787210.2024.2327517

C Moya-Alarcón, J R Azanza, J Barberán, R Ferrer, M Kwon, A Moreno, C Rubio-Terrés, M Gálvez-Santisteban

{"title":"Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain.","authors":"C Moya-Alarcón, J R Azanza, J Barberán, R Ferrer, M Kwon, A Moreno, C Rubio-Terrés, M Gálvez-Santisteban","doi":"10.1080/14787210.2024.2327517","DOIUrl":"10.1080/14787210.2024.2327517","url":null,"abstract":"Background: Invasive fungal infections (IFI) are associated with significant morbidity and mortality. The objective of this work was to compare the costs per adult patient, associated with intravenous isavuconazole (ISAV) followed by oral ISAV versus the regimen of liposomal amphotericin B followed by posaconazole (L-AMB→POSA) in the treatment of IFI. The comparison was conducted from the perspective of the Spanish National Health System (SNS).Methods: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration, hospitalization, laboratory tests and adverse events costs were evaluated from SNS perspective. Deterministic and probabilistic sensitivity analyzes were performed.Results: Total costs per-patient were €24,715.54 with ISAV versus €29,753.53 with L-AMB→POSA, resulting in cost-savings per patient treated with ISAV of €5,037.99 (-16.9%). Treatment costs of IFI remained lower for ISAV than for L-AMB→POSA across all sensitivity analyses (-7,968.89€ to -326.59€), being treatment duration the most influential parameter.Conclusion: According to the present model, the treatment of IFIs with ISAV would generate savings for the SNS compared to L-AMB→POSA. These savings are attributed to the shorter duration of IV treatment, reduced use of healthcare resources and lower costs associated with managing adverse effects when ISAV was employed.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How is ceftobiprole used in Canada: the CLEAR study final results. 头孢替吡咯在加拿大的使用情况：CLEAR 研究的最终结果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-15 DOI: 10.1080/14787210.2024.2374280

George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky

{"title":"How is ceftobiprole used in Canada: the CLEAR study final results.","authors":"George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky","doi":"10.1080/14787210.2024.2374280","DOIUrl":"10.1080/14787210.2024.2374280","url":null,"abstract":"Background: We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (Canadian Le adership on Antimicrobial Real-Life Usage) registry.Research design and methods: The authors review the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).Results: In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).Conclusions: In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the UK set to be hepatitis C free? 英国将成为无丙型肝炎国家吗？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2023-09-11 DOI: 10.1080/14787210.2023.2255751

Maria Fernanda Guerra-Veloz, Riham Soliman, Kosh Agarwal

引用次数: 0

Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection. 揭示微/纳米生物材料在治疗幽门螺旋杆菌感染中的潜在作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.1080/14787210.2024.2391910

Misagh Fathi Kisomi, Abbas Yadegar, Tara Shekari, Mohsen Amin, Antoni Llopis-Lorente, Chenguang Liu, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar, Mohammad Reza Zali, Mazda Rad-Malekshahi, Amir Hossein Miri, Michael R Hamblin, Matthias G Wacker

{"title":"Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection.","authors":"Misagh Fathi Kisomi, Abbas Yadegar, Tara Shekari, Mohsen Amin, Antoni Llopis-Lorente, Chenguang Liu, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar, Mohammad Reza Zali, Mazda Rad-Malekshahi, Amir Hossein Miri, Michael R Hamblin, Matthias G Wacker","doi":"10.1080/14787210.2024.2391910","DOIUrl":"10.1080/14787210.2024.2391910","url":null,"abstract":"Introduction: Helicobacter pylori causes stubborn infections and leads to a variety of stomach disorders, such as peptic ulcer, chronic atrophic gastritis, and gastric cancer. Although antibiotic-based approaches have been widely used against H. pylori, some challenges such as antibiotic resistance are increasing in severity. Therefore, simpler but more effective strategies are needed.Areas covered: In this review, basic information on functionalized and non-functionalized micro/nano biomaterials and routes of administration for H. pylori inhibition are provided in an easy-to-understand format. Afterward, in vitro and in vivo studies of some promising bio-platforms including metal-based biomaterials, biopolymers, small-molecule saccharides, and vaccines for H. pylori inhibition are discussed in a holistic manner.Expert opinion: Functionalized or non-functionalized micro/nano biomaterials loaded with anti-H. pylori agents can show efficient bactericidal activity with no/slight negative influence on the host gastrointestinal microbiota. However, this claim needs to be substantiated with hard data such as assessment of the biopharmaceutical parameters of anti-H. pylori systems and the measurement of diversity/abundance of bacterial genera in the host gastric/gut microbiota before and after H. pylori eradication.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of truenat assays for the diagnosis of pulmonary and extrapulmonary tuberculosis: a systematic review and meta-analysis. 用于诊断肺部和肺部外结核病的真菌检测评估：系统综述和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/14787210.2024.2389876

Shima Mahmoudi, Amir Hossein Sadegh Moghaddasi

{"title":"Evaluation of truenat assays for the diagnosis of pulmonary and extrapulmonary tuberculosis: a systematic review and meta-analysis.","authors":"Shima Mahmoudi, Amir Hossein Sadegh Moghaddasi","doi":"10.1080/14787210.2024.2389876","DOIUrl":"10.1080/14787210.2024.2389876","url":null,"abstract":"Background: Tuberculosis (TB) remains a significant global health concern, necessitating accurate and timely diagnostic methods. This study aimed to conduct a systematic review and meta-analysis to assess the diagnostic accuracy of Truenat assays for both pulmonary TB (PTB) and extrapulmonary TB (EPTB).Method: PubMed, Scopus, and Web of Science were systematically searched for studies comparing Truenat assays to Mycobacterium tuberculosis confirmation methods.Results: Comparing Truenat MTB assay with the Lowenstein-Jensen (LJ) culture, the pooled sensitivity and specificity were 86% (95% CI: 79-91%) and 86% (95% CI: 82-90%), respectively. For Mycobacterial Growth Indicator Tube (MGIT) culture comparison, pooled sensitivity was 88% (95% CI: 82-92%) with a specificity of 79% (95% CI: 57-92%). Compared to smear microscopy, Truenat assays displayed pooled sensitivity and specificity of 92% (95% CI: 78-98%) and 86% (95% CI: 64-95%). In comparison to Xpert MTB/RIF, Truenat assays exhibited a pooled sensitivity of 92% (95% CI: 80-97%) and a pooled specificity of 92% (95% CI: 56-99%) for PTB detection, and a pooled sensitivity of 94% (95% CI: 81-98%) and a specificity of 77% (95% CI: 32-96%) for the diagnosis of EPTB.Conclusion: This study underscores the potential of Truenat assays as valuable tools for diagnosing both PTB and EPTB.Prospero id: CRD42024526686.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0